Patient-reported outcomes (PROs) measure aspects of a patient's health status that come
directly from the patient, including health-related quality of life (HRQoL). HRQoL
instruments provide a means of assessing treatment benefit and can be important tools in
clinical research and practice.77 HRQoL is
becoming an increasingly important assessment tool in multiple myeloma, given the
improved survival outcomes from recent treatment advances. There are multiple
well-validated instruments available which can be used in clinical trials to facilitate
comparisons between treatments.75,77
*Validated for MM and widely used.
CIPN, chemotherapy-induced peripheral neuropathy; EORTC, European
Organisation for Research and Treatment of Cancer; FACT, Functional Assessment of Cancer
Therapy; MM, multiple myeloma; QLQ, quality of life questionnaire.
Multiple myeloma is an evolving disease state, and Amgen plans several substantive updates to the content of this site in the coming months. Please subscribe to be notified as these updates become available. Your email will not be used for any other purpose, and you can unsubscribe at any time.
Please send me a notification when myelomarevealed.com content is updated.